The Injectable Gel That Lights Up Tumors, Kills Them, and Trains Your Immune System

Every year, millions of cancer patients lie inside the narrow tube of an MRI machine while a nurse injects gadolinium into their veins. The contrast agent makes tumors glow on the scan, which helps surgeons find them and track whether treatment is working. But gadolinium has a problem: it accumulates in the body. The brain, the bones, the kidneys. The metal stays there, sometimes permanently. Some patients have developed nephrogenic systemic fibrosis, a condition where connective tissue grows uncontrollably. A safer alternative has been the goal of contrast-agent research for a decade.

Here is where it gets interesting. A team of researchers at Islamic Azad University in Tehran has compiled the evidence for a material that might replace gadolinium entirely, and it does more than just light up tumors on a scan. A single injection of this stuff could make your cancer visible on MRI, deliver therapy directly to the tumor, and train your immune system to attack it, all at the same time.

Background & Context

The standard approach to imaging a tumor is straightforward: inject a contrast agent, wait for it to circulate, and scan. Gadolinium-based agents have dominated for three decades. The metal ion’s seven unpaired electrons make water molecules relax faster, producing bright spots on MRI where blood flow is abnormal.

But gadolinium does not leave the body cleanly. Starting in the mid-2000s, researchers found that patients with kidney failure sometimes developed nephrogenic systemic fibrosis after receiving gadolinium agents. More recently, MRI studies have shown gadolinium accumulating in the brains of patients who received multiple doses. Nobody knows whether those deposits cause neurological damage, but the uncertainty has pushed the field to search for alternatives.

Meanwhile, cancer therapy has been heading in a different direction. The ideal cancer treatment does not just kill tumor cells. It also marks them for the immune system, remodels the hostile tumor environment, and lets doctors see if it is working: all without poisoning the rest of the body. Getting all of that into a single platform is the grand challenge of precision oncology.

What the Researchers Did

Motahareh Nazari and Keyvan Alavi carried out a systematic review of the literature on manganese-functionalized GelMA hydrogels, a mouthful of technical terms that boils down to a clever idea. GelMA (gelatin methacryloyl) is a modified form of gelatin, the same protein that gives Jell-O its wobble. It can be injected as a liquid and then crosslinked into a gel using light, right inside the body. The resulting hydrogel is biocompatible, biodegradable, porous enough to let molecules diffuse through, and structurally similar to the extracellular matrix that surrounds human cells.

The researchers reviewed the evidence for loading GelMA with various forms of manganese, the same trace element your body needs for bone development and blood clotting. Manganese ions have five unpaired electrons, giving them strong MRI contrast. Unlike gadolinium, manganese is an element your body already knows how to handle, with built-in metabolic pathways for uptake and excretion.

The review covers four main strategies for getting manganese into GelMA: simple physical mixing of nanoparticles into the hydrogel precursor solution, incorporation of MnO₂ nanosheets that break down in the acidic tumor environment, chemical chelation to lock the manganese in stable coordination complexes, and hybrid nanoplatforms that combine manganese with other therapeutic components like photosensitizers or immune adjuvants. Each approach has trade-offs in contrast quality, release kinetics, and safety.

What They Found

The review assembles evidence that manganese-based systems can do at least five distinct things inside a tumor, all from a single injection.

First, MRI contrast. Mn²⁺ ions shorten the T1 relaxation time of nearby water protons, producing positive contrast on scans: exactly what gadolinium does, but without the long-term tissue accumulation. In tumor-mimicking conditions (acidic pH, high glutathione), MnO₂ nanoparticles degrade to release Mn²⁺, creating smart contrast that activates only where the cancer is.

Second, chemodynamic therapy. In the acidic tumor microenvironment, Mn²⁺ catalyzes Fenton-like reactions that convert hydrogen peroxide into hydroxyl radicals: highly reactive molecules that damage proteins, lipids, and DNA in cancer cells. Because the reaction happens locally within the gel, healthy tissue sees less collateral damage.

Third, hypoxia relief. Tumors are oxygen-starved, which makes them resistant to radiation and many chemotherapies. MnO₂ nanoparticles react with endogenous hydrogen peroxide to produce oxygen. Incorporated into GelMA, they become local oxygen-generating reservoirs that re-oxygenate the tumor.

Fourth, glutathione depletion. Cancer cells protect themselves from oxidative damage by maintaining high levels of glutathione, the body’s master antioxidant. MnO₂ consumes glutathione directly, stripping tumors of their defense and making them vulnerable to oxidative therapies.

Fifth, immune activation: manganese amplifies the cGAS-STING pathway, a central alarm system in the innate immune response. When STING is activated, dendritic cells mature, antigen presentation improves, and cytotoxic T cells infiltrate the tumor. This can convert immunologically “cold” tumors (those invisible to the immune system) into “hot” ones that checkpoint inhibitors can finally attack.

Function	Manganese Component	Mechanism	Clinical Relevance
MRI contrast	Mn²⁺ ions or complexes	Shortens T₁ relaxation time of water protons	Visualizes tumor location, confirms gel placement, tracks degradation
Chemodynamic therapy	Mn²⁺ (Fenton catalyst)	Converts H₂O₂ to hydroxyl radicals (ROS)	Localized tumor cell death with reduced off-target toxicity
Hypoxia relief	MnO₂ nanoparticles	Reacts with H₂O₂ to generate O₂	Improves efficacy of radiation and oxygen-dependent therapies
Glutathione depletion	MnO₂	Oxidizes GSH, weakening antioxidant defenses	Sensitizes tumors to oxidative stress and chemotherapy
Immune activation	Mn²⁺	Amplifies cGAS-STING signaling pathway	Converts cold tumors to hot; enhances checkpoint inhibitor response

Why It Matters

The most clinically plausible use for these hydrogels, the authors argue, is preventing cancer recurrence after surgery. When a surgeon removes a tumor, they leave behind a cavity where microscopic cancer cells may remain. These residual cells are the seed of local recurrence, which carries a poor prognosis. An injectable hydrogel placed in the surgical cavity could serve triple duty: provide MRI-visible confirmation that the gel covers the full resection margin, release therapeutic manganese ions to kill residual cells, and prime the local immune system to hunt down any that escape.

The safety argument is straightforward. Gadolinium-based contrast agents are used in roughly 30 million MRI procedures per year worldwide. Every one of those injections deposits metal into the patient’s tissues. Manganese, as an essential trace element with regulated metabolic pathways, offers a fundamentally safer alternative, provided the release kinetics are properly controlled.

Here is a number that puts things in perspective. The FDA has approved 10 gadolinium-based contrast agents; at least 5 of them deposit in brain tissue. No manganese-based agent has been approved for clinical MRI in the US yet. That gap is a safety imperative as much as a scientific opportunity.

How It Could Change Our Lives

If these hydrogels clear clinical trials, the practical changes for patients would be measurable. Imagine a woman with early-stage breast cancer who undergoes a lumpectomy. Instead of leaving the surgical cavity empty, the surgeon injects a small volume of liquid that solidifies into a gel under the operating room lights. A postoperative MRI confirms the gel covers the full tumor bed. Over the next weeks, the gel slowly releases manganese that kills remaining cancer cells while training her immune system. A follow-up scan three months later shows the gel has degraded and been resorbed. No more tumors.

That scenario is speculative: none of this has been tested in humans yet. But the individual components have. GelMA hydrogels are already used in clinical tissue engineering. MnO₂ nanoparticles have shown safety in animal cancer models. The cGAS-STING pathway is the target of at least three ongoing clinical trials. The innovation here is bringing them together.

The Bigger Picture

What makes this review worth reading is not any single result (it is a review paper, not a primary study) but the framework it provides. The field of nanomedicine has a reputation for overclaiming. Every year brings another “revolutionary” nanoparticle platform that fades after the grant runs out. This review is refreshingly honest about the challenges: manganese toxicity at high doses, the difficulty of controlling release kinetics, the mechanical weakness of GelMA, and the regulatory nightmare of getting a combination product through the FDA.

The authors do not pretend these problems are solved. They list them, rank them, and suggest concrete paths forward: stronger chelators to prevent premature Mn²⁺ release, double-network hydrogels for mechanical reinforcement, AI-assisted formulation optimization, and, most importantly, a call for standardized metrics so that different labs can actually compare their results.

Limitations & What’s Next

The biggest gap is that nearly all the evidence comes from separate studies: GelMA hydrogels tested here, manganese nanoparticles tested there, STING activation studied in a different lab. Almost no studies integrate all three components in a single experiment. The authors cite exactly one paper, Jiang et al. (2025, ACS Nano), that loaded copper-manganese oxide nanoparticles into a GelMA implant for breast cancer immunotherapy. Promising, but not a clinical trial.

The next steps are straightforward but expensive: animal models of postsurgical tumor recurrence tracked by serial MRI, dose-finding studies, biodistribution and clearance studies, and eventually a first-in-human trial in patients with soft-tissue sarcoma or breast cancer, where the tumor cavity is accessible and recurrence risk is high.

Nazari and Alavi have drawn the roadmap. The question is whether anyone will build the road.

---

📄 Source: Nazari, M. & Alavi, K. “Manganese-Functionalized GelMA Hydrogels for MRI-Guided Immunotheranostics in Precision Oncology.” arXiv:2606.29599, June 2026. https://arxiv.org/abs/2606.29599